337965-61-4 Archives - Nitriles-buliding-blocks

Lacivita, Enza’s team published research in Bioorganic & Medicinal Chemistry in 25 | CAS: 337965-61-4

Bioorganic & Medicinal Chemistry published new progress about 337965-61-4. 337965-61-4 belongs to nitriles-buliding-blocks, auxiliary class Pyridine,Fluoride,Nitrile, name is 2-(6-Fluoropyridin-3-yl)acetonitrile, and the molecular formula is C7H5FN2, Quality Control of 337965-61-4.

Lacivita, Enza published the artcileStructure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [¹⁸F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide, Quality Control of 337965-61-4, the publication is Bioorganic & Medicinal Chemistry (2017), 25(1), 277-292, database is CAplus and MEDLINE.

Gastrin-releasing peptide receptors (GRP-Rs, also known as bombesin 2 receptors) are overexpressed in a variety of human cancers, including prostate cancer, and therefore they represent a promising target for in vivo imaging of tumors using positron emission tomog. (PET). Structural modifications of the non-peptidic GRP-R antagonist PD-176252 ((S)-1a) led to the identification of the fluorinated analog (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide ((S)-1m) that showed high affinity and antagonistic properties for GRP-R. This antagonist was stable in rat plasma and towards microsomal oxidative metabolism in vitro. (S)-1m was successfully radiolabeled with fluorine-18 through a conventional radiochem. procedure. [¹⁸F](S)-1m showed high affinity and displaceable interaction for GRP-Rs in PC3 cells in vitro.

Referemce:
https://en.wikipedia.org/wiki/Nitrile,
Nitriles – Chemistry LibreTexts

Nuellen, Max Peter et al. published their patent in 2021 |CAS: 337965-61-4

The Article related to organic compound electronic device oled semiconductor layer display device, Electric Phenomena: Semiconductor Junctions and Devices and other aspects.Related Products of 337965-61-4

On December 30, 2021, Nuellen, Max Peter; Schulze, Benjamin; Wudarczyk, Jakob Jacek published a patent.Related Products of 337965-61-4 The title of the patent was Organic compounds for use in organic electronic devices (OLED), semiconductor layer and display device. And the patent contained the following:

The present invention relates to a compound of formula I and an organic electronic device comprising a semiconductor layer which comprises a compound of formula I. The experimental process involved the reaction of 2-(6-Fluoropyridin-3-yl)acetonitrile(cas: 337965-61-4).Related Products of 337965-61-4

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

McCauley, John A. et al. published their patent in 2001 |CAS: 337965-61-4

The Article related to benzimidazole preparation analgesic, benzyl benzimidazole preparation glutamate receptor antagonist, heteroaryl benzimidazole preparation nmda nr2b antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Formula: C7H5FN2

On May 10, 2001, McCauley, John A.; Theberge, Cory R.; Liverton, Nigel J.; Claremon, David A.; Claiborne, Christopher F. published a patent.Formula: C7H5FN2 The title of the patent was Preparation of 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists. And the patent contained the following:

Novel benzimidazoles, substituted in the 2-position by substituted benzyl groups or heteroaryl groups, (I) [wherein R1, R2, R4, and R5 = independently H, Cl, F, OH, OMe, CF3, OCF3, NH2, CN, NO2, (amino)alkyl, aryl, alkylcarbonylamino, oxohydroxydibenzopyranyl-substituted carboxyphenylthioureido or carbonylaminoalkylcarbonylamino, R6SO2NH, R6SO2NMe, or R6SO2NHCH2; R3 = H, OH, NH2, alkylamino, arylamino, or :O; R6 = (un)substituted alkyl, (phenyl)alkenyl, Ph, naphthyl, or heterocyclic group; Y = O, NH, (CH2)nCO(CH2)n, or (CH2)nCHR3(CH2)n; n = 0-5; Ar may be substituted with 0-3 N atoms in positions 2, 3, 5, or 6] were prepared as effective NMDA NR2B glutamate receptor antagonists. For example, cycloaddition of phenylenediamine and (4-phenoxyphenyl)acetic acid in presence of EDC and HOBt in DMF afforded 2-(4-phenoxybenzyl)-1H-benzimidazole. Exptl. protocols for assessing the inhibition of NR1A/2B NMDA receptor activation (FLIPR assay) and determining the apparent dissociation constants against the human NR1A/NR2B receptor (binding assay) are given (no data). I are useful for relieving pain and treating depression, schizophrenia, Parkinson’s disease, or stroke (no data). The experimental process involved the reaction of 2-(6-Fluoropyridin-3-yl)acetonitrile(cas: 337965-61-4).Formula: C7H5FN2

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts

Kilburn, John Paul et al. published their patent in 2014 |CAS: 337965-61-4

The Article related to benzamide preparation p2x7 receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Electric Literature of 337965-61-4

On April 17, 2014, Kilburn, John Paul; Rasmussen, Lars Kyhn; Jessing, Mikkel; Eldemenky, Eman Mohammed; Chen, Bin; Jiang, Yu; Hopper, Allen T. published a patent.Electric Literature of 337965-61-4 The title of the patent was Preparation of benzamides as P2X7 receptor antagonists. And the patent contained the following:

The title compounds I [R1 = Ph, pyridyl, pyrazinyl, etc.; R2 = cycloalkyl, alkoxy, Ph, etc.; R3 = H, F, alkyl, fluoroalkyl; or R2 and R3 can be combined with the carbon to which they are attached to form cyclohexyl, piperazinyl, piperidinyl, etc.; R4 = halo, fluoroalkyl, CN, etc.; R5 = halo, alkyl, fluoroalkyl, etc.; n = 0-3], useful in the treatment of diseases related with the activity of P2X7 receptor, were prepared For example, amidating [4-(4-chloro-phenyl)-tetrahydro-pyran-4-yl]-methylamine with 2,3-dimethylbenzoyl chloride afforded 66% II. Compounds I were tested in vitro for their ability to act as antagonists to the P2X7 receptor (data given for representative compounds I). Pharmaceutical composition comprising compound I is disclosed. The experimental process involved the reaction of 2-(6-Fluoropyridin-3-yl)acetonitrile(cas: 337965-61-4).Electric Literature of 337965-61-4

Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts